AbGn-168H Neihulizumab
100
100
100
0
0
Phase II
Phase II POC ready and to bridge with s.c. version.
100
100
30
0
0
Phase II
Phase II Inflammatory T Cell Control Antibody for TNF-i and/or Entyvio or JAK-i Refractory Ulcerative Colitis, Phase ll ongoing.
100
50
0
0
0
Phase I
Phase I Inflammatory T Cell Control Antibody for Steroid Refractory-Acute Graft versus Host Disease (GvHD) , Phase 1 ongoing (in patients).
AbGn-268 Leiolizumab
80
0
0
0
0
Preclinical
Preclinical Potency improved version of AbGn-168H for Chronic Inflammatory Disease
AbGn-107
100
50
0
0
0
Phase I
Phase I Antibody Drug Conjugate for Gastrointestinal Cancer, currently in cohort expansion phase of clinical study for efficacy assessment in advanced Gastric Cancer, Pancreatic Cancer, Biliary Cancer and Colorectal Cancer patients
AbGn-207
50
0
0
0
0
Preclinical
Preclinical CAR-T for Antigen Positive Cancer
Discover, Develop and Deliver
Innovative Therapies That Make an Impact
b2/20180914134948v4ecbwM755.png)
b2/20180914134949966ao04Yh7.png)
A proof-of-principle study to test the efficacy and safety of Neihulizumab in patients with moderate to severe active ulcerative colitis and who have failed or are intolerant to anti-TNFα and/or anti-integrin therapy
b2/201809141349509ugarxwbm8.png)
b2/201809141349508f0tv9ZK910.png)
Study evaluating the safety, signs of efficacy, pharmacokinetics, receptor occupancy and pharmacodynamics biomarkers of Neihulizumab in patients with steroid-refractory acute GvHD
b2/20180914134950ewk4tfHeH11.png)
b2/20180914134951e1dsx2ihp12.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
b2/20180914134951f2zzjoyyL13.png)
b2/20180914134951yf3pllMYq14.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
b2/20180914134951r1ahteBHY15.png)
b2/20180914134952p7kr3j02M16.png)
This study is to define the safety profile and to determine the maximum tolerated dose (MTD) and preliminary efficacy of AbGn-107
AltruBio to present at Biotech Showcase Digital 2021.
AltruBio pioneers the development of a number of agonist antibodies targeting the PSGL-1 immune checkpoint regulator. Its lead molecule, Neihulizumab has now demonstrated clinical results in sr-aGVHD, Ulcerative Colitis, Psoriasis, and Psoriatic Arthritis.
AltruBio Announces First Patient Dosed in Phase 1b Study of Neihulizumab in Patients with Steroid-Refractory Acute Graft-versus-Host Disease.
2F, No. 36, Lane. 358, Juikuang Road
Neihu, Taipei, Taiwan 11492
Tel: (886)-2-2627-2707
E-mail: info@altrubio.com
555 Twin Dolphin Drive, Suite #310,
Redwood City, CA94065 U.S.A.
Tel: (650)453-3462
E-mail: info@altrubio.com
Kingsfordweg 103, 1043 GP Amsterdam
The Netherlands
Tel: +31 (0)88-1009333
E-mail: abgcoop@abgenomics.nl
